Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis - Top_Commentaries - MDSpire

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis

  • By

  • Vladimir Zah

  • Dimitrije Grbic

  • Filip Stanicic

  • June 30, 2026

  • 0 min

Share

3 Topic Commentaries

Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning

  • Dr. Jane Smith, MD, Neurocritical Care Physician, MD

    Assistant Professor of Neurology

    University Hospital of Critical Care Medicine

    “While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”

    [Source]
  • Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD

    Senior Research Fellow

    Institute for Brain Health Research

    “In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”

    [Source]
  • Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH

    Public Health Policy Advisor

    National Stroke & Infection Control Coalition

    “Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”

    [Source]

Original Source(s)

Related Content